News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Conference News AHA 2020 One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3 Michael O'Riordan November 13, 2020
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2018 REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides Todd Neale November 10, 2018
News Conference News AHA 2018 New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening Michael O'Riordan November 10, 2018
News Conference News ACC 2018 Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis Michael O'Riordan March 14, 2018
News Conference News AHA 2017 Long-Awaited Hypertension Guidelines Released at AHA Todd Neale November 13, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016